Table 5.
The estimated pharmacokinetic parameters and relative bioavailability (%) of Duloxetine HCl following the intranasal and the transdermal application of DUL-E1 (test treatments) versus the oral administration of DUL aqueous solution (reference treatment) in rats (mean ± s.d., n = 6).
| Pharmacokinetic parameters | Intranasal DUL-E1 | Transdermal DUL-E1 | Oral DUL aqueous solution |
|---|---|---|---|
| Cmax (ng/mL) | 251 ± 18.6 | 248 ± 15.9 | 135 ± 8.6 |
| Tmax (h) | 2 (2–2) | 4 (2–4) | 2 (2–2) |
| Tel (h) | 20.4 ± 0.6 | 22.3 ± 0.8 | 12 ± 0.4 |
| MRT0-∞ (h) | 29.7 (29.2–30.4) | 32.7 (31.9–33.5) | 18 (17–18.7) |
| AUC0–72 (ng.h/mL) | 6273 ± 267 | 6842.5 ± 230 | 2416.3 ± 62 |
| AUC0-∞ (ng.h/mL) | 6884.5 ± 275 | 7703.7 ± 239 | 2456.3 ± 68 |
| Relative Bioavailability based on AUC0-∞ (%) | 280.28 | 313.63 | – |